TickerFacts.

Calidi Biotherapeutics, Inc. (CLDI): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$1.65M
Year ended 2025-12-31
$1.71M
Trailing 12 months to 2026-06-30
2024-12-31: $1.53M2025-12-31: $1.65M$1.65M
2024-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$1.65M+7.6%2026-03-27, From 2025-01-01
2024-12-31$1.53Mn/a2026-03-27, From 2024-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Calidi Biotherapeutics, Inc. (CLDI)2025-12-31$1.65M+7.6%
Creative Medical Technology Holdings, Inc. (CELZ)2024-12-31$56.0K0.0%
VivoSim Labs, Inc. (VIVS)2026-03-31$215.0K-19.2%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$1.42M-13.8%
BioAtla, Inc. (BCAB)2025-12-31$373.0K-59.7%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$117.1K+2.8%
Curis Inc (CRIS)2025-12-31$169.0K-16.7%
Atara Biotherapeutics, Inc. (ATRA)2025-12-31$2.12M-58.1%
BioCardia, Inc. (BCDA)2025-12-31$24.0K-64.2%

Compare CLDI, CELZ, VIVS, SCNI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗